

A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?

Jennifer Barber,^{1*} Tricia M. McKeever,^{2*} Sarah E. McDowell,³
Jennifer A. Clayton,⁴ Robin E. Ferner,³ Richard D. Gordon,⁵
Michael Stowasser,⁵ Kevin M. O'Shaughnessy,⁶ Ian P. Hall¹ &
Mark Glover¹

¹Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham NG7 2UH,

²Division of Epidemiology and Public Health, University of Nottingham, Nottingham NG5 1PB, ³West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham B18 7QH, ⁴Department of

Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK,

⁵Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Brisbane,

Australia and ⁶Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge CB2 2QQ, UK

Correspondence

Dr Mark Glover PhD MB BChir, Division of Therapeutics and Molecular Medicine, Queen's Medical Centre, Nottingham NG7 2UH, UK.

Tel.: 00441159249924

Fax: 00441159709995

E-mail: mark.glover@nottingham.ac.uk

*Joint first authors.

Keywords

hypokalaemia, hypokalemia, hyponatraemia, hyponatremia, thiazide, thiazide-like

Received

10 June 2014

Accepted

13 August 2014

Accepted Article

Published Online

19 August 2014

AIMS

Hyponatraemia is one of the major adverse effects of thiazide and thiazide-like diuretics and the leading cause of drug-induced hyponatraemia requiring hospital admission. We sought to review and analyze all published cases of this important condition.

METHODS

Ovid Medline, Embase, Web of Science and PubMed electronic databases were searched to identify all relevant articles published before October 2013. A proportions meta-analysis was undertaken.

RESULTS

One hundred and two articles were identified of which 49 were single patient case reports. Meta-analysis showed that mean age was 75 (95% CI 73, 77) years, 79% were women (95% CI 74, 82) and mean body mass index was 25 (95% CI 20, 30) kg m⁻². Presentation with thiazide-induced hyponatraemia occurred a mean of 19 (95% CI 8, 30) days after starting treatment, with mean trough serum sodium concentration of 116 (95% CI 113, 120) mM and serum potassium of 3.3 (95% CI 3.0, 3.5) mM. Mean urinary sodium concentration was 64 mM (95% CI 47, 81). The most frequently reported drugs were hydrochlorothiazide, indapamide and bendroflumethiazide.

CONCLUSIONS

Patients with thiazide-induced hyponatraemia were characterized by advanced age, female gender, inappropriate saluresis and mild hypokalaemia. Low BMI was not found to be a significant risk factor, despite previous suggestions. The time from thiazide initiation to presentation with hyponatraemia suggests that the recommended practice of performing a single investigation of serum biochemistry 7–14 days after thiazide initiation may be insufficient or suboptimal. Further larger and more systematic studies of thiazide-induced hyponatraemia are required.

Introduction

Thiazide and thiazide-like diuretics, although they differ in chemical structure, all inhibit the thiazide-sensitive sodium–chloride co-transporter, NCC, in the distal convoluted tubule of the kidney [1]. Since the demonstration of their anti-hypertensive effect in 1958 [2] they have been widely used in the management of hypertension, and continue to be so, notwithstanding their recent and controversial demotion to step 3 in UK hypertension guidance [3, 4]. Their benefits on all-cause mortality are equal to those of angiotensin-converting enzyme (ACE) inhibitors and calcium channel antagonists [5, 6].

However thiazide diuretics often cause adverse effects, of which thiazide-induced hyponatraemia is amongst the most clinically important [7]. Thiazide-induced hyponatraemia may also represent a scientifically important paradigm of the dysregulation of sodium (and water) transport within the distal nephron [8].

Thiazide diuretics are the most common cause of drug-induced hyponatraemia in secondary care [9]. Severe thiazide-induced hyponatraemia causes debilitating symptoms such as confusion, falls and seizures, and can sometimes be fatal [7]. Thiazide-induced hyponatraemia necessitating hospital admission is common enough to suggest that current monitoring regimens are suboptimal [9]. Importantly, the mechanism of thiazide-induced hyponatraemia is also poorly understood. Mean serum sodium concentration in the total treated population is virtually unchanged by thiazide therapy [10], implying that thiazide-induced hyponatraemia occurs in a susceptible subgroup. However this subgroup cannot be prospectively identified at present and so thiazide-induced hyponatraemia is largely unpredictable at the point of thiazide initiation. We therefore set out to undertake a systematic review and meta-analysis of all thiazide-induced hyponatraemia reports published to date in order to summarize and reflect on the current understanding of this condition.

Methods

Search strategy

Medline, Embase, Web of Science and PubMed databases were searched on 1 October 2013 without limitation on language. The Ovid interface was used to search Medline and Embase using the terms ‘thiazide AND hyponatr\$emia’, ‘thiazide-induced hyponatr\$emia’ and ‘thiazide-associated hyponatr\$emia’. Web of Science and PubMed were searched using the terms ‘(thiazide AND (hyponatraemia OR hyponatraemia)), ‘(thiazide-induced AND (hyponatraemia OR hyponatraemia)), ‘(thiazide-associated AND (hyponatraemia OR hyponatraemia))’. Database searches were also undertaken with the term ‘thiazide’ replaced alternatively by either ‘indapamide’ or

‘chlortalidone’. Articles that cited or were cited by the included studies were also screened to identify any further relevant studies. Duplicated results and studies containing no primary data or non-human data only were removed. The conventional definition for hyponatraemia of serum sodium concentration ≤ 135 mM was used [11, 12].

Data extraction

Two authors (JB and MG) independently reviewed the titles, abstracts and full text of identified papers. References of all full text papers were searched to identify any additional pertinent papers. Disagreements were resolved by discussion. Data extraction was performed using a structured template to collect information on study design (including location of study and year of publication) and thiazide-induced hyponatraemia phenotype including age, gender, presenting symptoms, drug history including concomitant drug use and laboratory findings. Methodological quality was independently rated by two authors (JB and MG) using a modified version scale developed for observational studies [13]. The range of possible scores was 0–12.

Data analysis

Study parameters which were reported in more than 1% of patients are presented. We excluded from the analysis any measurement given qualitatively as ‘normal’ without any indication of the value itself or the reference range. For publications in which more than one patient was reported a proportions meta-analysis was conducted to look at the weighted frequency of clinical phenotype, drug history and laboratory findings for the combined number of papers contributing to each separate analysis. A random effects model was used to determine 95% confidence intervals (CI), using the DerSimonian & Laird method to calculate weights [14]. Study heterogeneity was assessed using I^2 scores. Causes of high levels of heterogeneity were explored by dividing the following variables at the median level: quality score, year of publication, and age of study population. Evidence for the possibility of publication bias was assessed by funnel plots. Single case reports were simply summarized.

The presentation of the meta-analyses adhered to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) consensus statement [15]. All proportional analyses were performed using the Stats Direct® statistical software package version 2.7.9 and Stata® version 12 for the meta-analyses of mean values.

Results

Database searches resulted in 1359 citations. After exclusion of duplicates and articles where data were non-human or irrelevant to thiazide-induced hyponatraemia in adults, 102 articles remained (median date of publication




Figure 1

Flow diagram of steps in systematic review in PRISMA format

was 1998, range 1962–2013) and were analyzed (Figure 1). Of the 102 articles analyzed, 49 were single case reports [16–64] (Table S1) and the remaining 52 articles ranged from two to 1802 patients [10, 65–116] (Table S2). Four papers were also removed because the same study population was already represented in the 102 articles included in the review [10, 117–119].

The mean value for quality score was 4.0 (range 1–8) for studies included in the meta-analysis and 3.2 for single case reports (range 1–6). The main reasons for low quality scores were a lack of clearly stated inclusion and exclusion criteria, absence of documented patient consent and/or ethical approval, a lack of inclusion of patient perception, a lack of clarity regarding the name, dose and duration of thiazide therapy and whether thiazide-induced hyponatraemia patients represented a consecutive series treated consistently by the same physician(s) or at a single institution.

Meta-analysis findings

Clinical characteristics Patients with thiazide-induced hyponatraemia had a mean age of 75 years (pooled estimate, 95% CI 73, 77 years, based on 36 studies and 2840 patients, Figure S1), 79% were women (95% CI 74, 82%, $I^2 = 65%$, based on 43 studies and 3269 patients, Figure S2) and mean body mass index was 25 kg m^{-2} (pooled estimate, 95% CI 20, 30 kg m^{-2} , $I^2 = 100%$, based on two studies and 2025 patients, Figure S3). Thiazide-induced hyponatraemia was first detected a mean of 19 days (pooled estimate, 95% CI 8, 30 days, $I^2 = 97%$, based on 19 studies and 446 patients, Figure S4) after starting thiazide

treatment (Table 1). Sensitivity analysis by removal of studies with delay to thiazide-induced hyponatraemia >100 days also showed the time to detection was greater than the standard 7–14 day serum electrolyte monitoring period (17 days, 95% CI 6, 28 days, based on 14 studies with 415 patients). The levels of heterogeneity were explored by quality score, year of publication and age of patients. However none of these factors could explain the high levels of heterogeneity (Table S3).

Clinical characteristics of patients with thiazide-induced hyponatraemia are presented in Table 2 (meta-analyses graphs Figures S5 to S14). The most frequently reported symptoms at presentation were: falls (48%, 95% CI 20, 77%, $I^2 = 84%$, based on five studies and 252 patients), fatigue (46%, 95% CI 21, 72%, $I^2 = 92%$, based on eight studies and 333 patients), weakness (45%, 95% CI 32, 58%, $I^2 = 49%$, based on 14 studies and 247 patients), confusion (44%, 95% CI 33, 56%, $I^2 = 85%$, based on 22 studies and 710 patients) nausea (36%, 95% CI 24, 48%, $I^2 = 76%$, based on 14 studies and 405 patients) and vomiting (35%, 95% CI 25, 45%, $I^2 = 68%$, based on 13 studies and 549 patients). Also reported were other neurological symptoms, dizziness, unconsciousness and seizures (Table 2). Analyses of clinical characteristics revealed substantial heterogeneity between studies which was not explained by quality score, year of publication or age of patient (Table S4).

Co-morbidities The most commonly reported comorbidities included cardiovascular disease (49%, 95% CI 33, 65%, $I^2 = 72%$, based on 12 studies and 284 patients,

Table 1

Analysis of pooled data of the age, gender, BMI and duration of thiazide therapy of patients with thiazide-induced hyponatraemia

Variable	Mean	95% CI	I ² (%)	Pop Studies/Patients	n	Summary of case report data		
						Mean	SD	Range
Gender (Female)*	0.79	0.74, 0.82	65	43/3269	32 (66%)			
Age (years)	74.9	73.0, 76.8	93	36/2840	48	63.8	14.8	31–88
BMI (kg m ⁻²)	24.9	20.0, 29.8	100	2/2025	3	21.3	2.8	18.2–23.7
Time to TIH (days)	19.0	7.9, 30.1	97	19/446	26	189	817	1–3650

*Data expressed as proportion. BMI, body mass index; CI, confidence interval; n, number of patients in single case reports; Pop, contributing population to the meta-analyses, number of studies/total number of patients with the studies; SD, standard deviation; TIH, thiazide induced hyponatraemia.

Table 2

Meta-analysis of the symptoms reported at presentation in patients with thiazide-induced hyponatraemia

Symptoms	Prop	95% CI	I ² (%)	Pop Studies/Patients	Summary of case report data	
					n	%
Falls	0.48	0.20, 0.77	84	5/252	2	4
Fatigue	0.46	0.21, 0.72	92	8/333	18	38
Weakness	0.45	0.32, 0.58	49	14/247	13	27
Confusion	0.44	0.33, 0.56	85	22/710	16	33
Nausea	0.36	0.24, 0.48	76	14/405	10	21
Neurological symptoms	0.51	0.22, 0.80	76	8/37	10	21
Vomiting	0.35	0.25, 0.45	68	13/549	9	19
Dizziness	0.31	0.15, 0.51	92	8/488	5	10
Unconsciousness	0.30	0.15, 0.48	75	11/181	13	27
Seizures	0.19	0.08, 0.33	84	10/405	10	21

Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions. CI, confidence interval; n, number of single case reports reporting the variable listed; Pop, contributing population to the meta-analyses, number of studies/total number of patients with the studies; Prop, proportion.

Figure S15) and diabetes mellitus (27%, 95% CI 14, 42%, I² = 99%, based on nine studies and 3029 patients, Figure S16). Analyses of comorbidities revealed substantial heterogeneity between studies which was not explained by quality score, year of publication or age of patient (Table S3). A single study of 1802 patients reported the prevalence of gastro-oesophageal reflux disease (24%), hyperlipidaemia (47%) and urinary tract infection (24%) [103].

Medication history Thiazide-induced hyponatraemia was reported in association with a wide range of thiazide/thiazide-like drugs (Table 3, meta-analyses graphs in Figures S17 to S22). By far the most frequently implicated was hydrochlorothiazide either alone (68%, 95% CI 52, 82%, I² = 97%, based on 19 studies and 2583 patients) or in combination with amiloride (as Moduretic®, 73%, 95% CI 57, 87%, I² = 92%, based on 19 studies and 633 patients) or triamterene (as Dyazide®, 18%, 95% CI 8, 32%, I² = 36%, based on three studies and 59 patients). Other thiazide/thiazide-like drugs implicated were indapamide, bendroflumethiazide (bendrofluazide), and chlortalidone. Analyses of which individual thiazide/thiazide-like drugs were

associated with hyponatraemia revealed high levels of heterogeneity between studies and this was not explained by quality score, year of publication or age of patient (Table S4).

Details of concurrent non-thiazide medication in patients with thiazide-induced hyponatraemia are presented in Table 3 (meta-analyses graphs Figures S23 to S28). Commonly reported non-thiazide co-prescriptions were angiotensin II receptor antagonists (59%, 95% CI 0, 96%, I² = 99%, based on three studies and 1844 patients), angiotensin converting enzyme (ACE) inhibitors (51%, 95% CI 27, 75%, I² = 96%, based on five studies and 2000 patients), non-thiazide diuretics (e.g. loop and potassium sparing diuretics) (58%, 95% CI 19, 91%, I² = 86%, based on five studies and 1815 patients), non-steroidal anti-inflammatory drugs (NSAIDs) (33%, 95% CI 18 to 49%, I² = 89%, based on six studies and 2036 patients) and anti-depressants (32%, 95% CI 19, 47%, I² = 68%, based on six studies and 1882 patients). While selective serotonin re-uptake inhibitors (SSRIs) are associated with hyponatraemia, there was insufficient data to determine what proportion of the anti-depressant medication reported were SSRIs. Analyses of polypharmacy demonstrated high

Table 3

Meta-analysis of the drug history in patients with thiazide-induced hyponatraemia

Drugs	Prop.	95% CI	I ² (%)	Pop Studies/Patients	Summary of case study data	
					n	%
Thiazide or thiazide-like drug						
Moduretic® (HCTZ with amiloride)	0.73	0.57, 0.87	92	19/633	8	16
HCTZ	0.68	0.52, 0.82	97	19/2583	14	29
Bendroflumethiazide (bendrofluazide)	0.52	0.15, 0.88	97	8/429	4	8
Indapamide	0.47	0.23, 0.72	99	8/1313	2	4
Dyazide® (HCTZ with triamterine)	0.18	0.08, 0.32	36	3/59	4	8
Chlortalidone	0.07	0.02, 0.14	85	6/2174	2	2
HCTZ with losartan	0 studies				2	4
Other drugs						
ARB	0.59	0.00, 0.96	99	3/1844	3	6
Non-thiazide diuretics	0.58	0.19, 0.91	86	5/1815	3	6
ACE inhibitor	0.51	0.27, 0.75	96	5/2000	6	12
NSAID	0.33	0.18, 0.49	89	6/2036	2	4
Antidepressants	0.32	0.19, 0.47	68	6/1882	4	8
Potassium supplements	0.16	0.15, 0.18		2/1805	2	2

Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions of those studies that reported each given variable at least once. ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; HCTZ, hydrochlorothiazide; n, number of single case reports reporting the variable listed; NSAID, non-steroidal anti-inflammatory drug; Pop, contributing population to the meta-analyses, number of studies/total number of patients with the studies; Prop, proportion.

Table 4

Meta-analysis of laboratory characteristics in patients with thiazide-induced hyponatraemia

	Mean	95% CI	I ² (%)	Contributing population Studies/Patients	Summary of case study data	
					n	Mean (SD)
Serum sodium (mM)	116.4	113.4, 119.5	99	37/1042	48	111.2 (8.2)
Serum potassium (mM)	3.3	3.0, 3.5	97	28/902	41	3.3 (1.0)
Serum creatinine (µmol l ⁻¹)	76.8	64.1, 89.4	99	17/504	28	75.2 (30.2)
Serum osmolality (mosm kg ⁻¹)	240.4	235.9, 244.8	80	11/229	28	221.3 (65.3)
Urine sodium (mM)	64.0	47.0, 81.0	94	13/98	22	55.2 (39.5)
Urine osmolality (mosm kg ⁻¹)	401.5	370.3, 432.6	81	14/322	27	438.3 (200.7)

Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions. CI, confidence interval; n, number of single case reports reporting the variable listed; SD, standard deviation.

levels of heterogeneity between studies, which was not explained by quality score, year of publication or age of patient (Table S5).

Laboratory characteristics

As shown in Table 4 (Figures S29 to S34), thiazide-induced hyponatraemia patients had severe hyponatraemia, with a mean trough serum sodium concentration of 116 mM (95% CI 113, 120 mM, I² = 99%, based on 37 studies and 1042 patients), mild hypokalaemia, with serum potassium 3.3 mM (95% CI 3.0, 3.5 mM, I² = 97%, based on 28 studies and 902 patients) and normal renal function, serum creatinine 76.8 µmol l⁻¹ (95% CI 64.1, 89.4 µmol l⁻¹, I² = 99%, based on 17 studies and 504 patients). Corresponding urinary electrolyte data indicated inappropriate saluresis, with urinary sodium concentration 64 mM (95%

CI 47, 81 mM, I² = 94%, based on 13 studies and 98 patients). Mean serum and urine osmolalities were 240 mosm kg⁻¹ (95% CI 236, 245 mosm kg⁻¹, I² = 80%, based on 11 studies and 229 patients) and 402 mosm kg⁻¹ (95% CI 370, 432 mosm kg⁻¹, I² = 81%, based on 14 studies and 322 patients), respectively. In most analyses of laboratory characteristics there were high levels of heterogeneity between studies, which were not explained by quality score, year of publication or age of patient (Table S6).

Discussion

We present, to our knowledge, the first systematic review and meta-analysis of the observational literature regarding the clinical and laboratory characteristics of

thiazide-induced hyponatraemia. Patients with thiazide-induced hyponatraemia were characterized by advanced age, female gender, inappropriate saluresis and mild hypokalaemia. In addition, patients had a normal BMI, in contrast to suggestions that such patients tend to be underweight [7].

The most notable finding was of the delay from thiazide initiation to diagnosis of thiazide-induced hyponatraemia which averaged 19 days (95% CI 8, 30 days, Figure S4). Current best practice is to measure serum biochemistry 1–2 weeks after thiazide initiation [120]. Our data suggest that either best practice is not followed [121], or that testing at 1–2 weeks fails to detect some patients who go on to develop thiazide-induced hyponatraemia [9] in which case changes in monitoring schedules might improve current practice. Without data reporting either the frequency of routine biochemical monitoring or the levels of serum sodium from such monitoring it is not possible to recommend confidently what the optimal timing of a single electrolyte check should be or whether there would be merit in performing a second electrolyte measurement after the initial fortnight following thiazide initiation, e.g. at 3–4 weeks. Since in a few cases, severe hyponatraemia developed many months or even years after thiazide initiation, it would be prudent to measure serum electrolyte concentrations whenever patients treated with thiazides develop symptoms suggestive of hyponatraemia, regardless of the duration of thiazide therapy.

Mild hypokalaemia accompanying thiazide-induced hyponatraemia may occur simply as a consequence of excessive saluresis and consequent electrogenic exchange of potassium for sodium in the collecting duct. Additional mechanisms may also contribute: for example (i) aldosterone activation of the distal nephron, as is to be expected and not uncommonly seen with thiazide-induced hypokalaemia and hyperaldosteronism [122], or (ii) With No lysine protein Kinase (WNK) regulation of the renal outer-medullary potassium channel (ROMK) in the collecting duct and the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal convoluted tubule as has been proposed for the hyperkalaemia seen in Gordon syndrome [123], a Mendelian disorder of thiazide-responsive hypertension and metabolic acidosis.

Hyperlipidaemia was the most common comorbidity. Whilst severe hyperlipidaemia is a well-recognized cause of pseudo-hyponatraemia in older studies that relied on methods such as flame photometry to measure serum sodium concentration, most dyslipidaemia is very unlikely to affect modern assay methods. The second most common comorbidity was diabetes mellitus. Plasma glucose concentration was reported infrequently and it is possible that hyperglycaemia could have contributed to hyponatraemia in some cases. Since for the vast majority of patients reported the indication for

thiazide prescription was hypertension and presentation was with symptomatic hyponatraemia it is not possible to make meaningful conclusions either regarding thiazide-induced hyponatraemia when thiazide prescriptions were for indications other than hypertension or the differences between symptomatic vs. non-symptomatic patients.

Several of the medicines most commonly co-prescribed with thiazides among studies included in this meta-analysis, such as ACE inhibitors, AT₁ receptor antagonists, NSAIDs and some anti-depressants, are associated with hyponatraemia through well-described mechanisms. This raises the possibility that some cases of apparent thiazide-induced hyponatraemia could result from pharmacodynamic interactions of these drugs with thiazides. It was also notable that hypokalaemia was seen despite the frequency of concurrent therapy with ACE inhibitors, AT₁ receptor antagonists and potassium supplements.

The finding of a normal serum creatinine concentration is unexpected in such an elderly cohort at higher than average vascular risk, many of whom also took ACE inhibitors, angiotensin receptor blockers (ARBs) and/or NSAIDs. BMI was normal, so low muscle mass is unlikely to predominantly account for this raising the possibility of a dilutional component to the observed serum creatinine concentrations. Thus in addition to inappropriate saluresis and inappropriately high urinary osmolarity, inappropriately low serum creatinine concentration is consistent with volume expansion and the overall phenotype could therefore be alternatively described as having much in common with thiazide-induced syndrome of inappropriate anti-diuretic hormone secretion (SIADH) [124].

There are significant limitations to this systematic review. Included studies were very heterogeneous with respect to the detail of their description, specific parameters recorded and laboratory methods used and this did not appear to be explained by either individual study quality, median date of publication or whether the study pertained to a particular 'specialist group'. One possible explanation for the high level of heterogeneity found in the analyses may be the local prescribing habits of the areas in which these often small studies were undertaken given that case series usually focused on small numbers from a single institution over a relatively short project interval. Case reports were excluded from our meta-analysis but we accept that a case report may describe unusual but important presenting clinical and laboratory characteristics of patients with thiazide-induced hyponatraemia. For this reason we have presented a summary of the case report data alongside that for the meta-analysis in Tables 1–4. It is also possible that some publications were not identified by our search of the four principal databases used. However the extensive searches and the searching of reference lists limits the possibility of many missing articles. Publication bias is still a possibility.

However none of the funnel plots from the meta-analyses indicated that this was a problem. The vast majority of reports detailed patients who had been admitted to hospitals with symptomatic hyponatraemia and it is therefore likely that asymptomatic and non-hospitalized patients with thiazide-induced hyponatraemia are underrepresented.

There are also specific issues with respect to the phenotypic parameters measured by observational studies. Advanced age is confounded by the prescribing of thiazides to older patients and the over-representation of females may be confounded by the shorter life expectancy of males. Although oestrogens do affect sodium transport via the thiazide-sensitive NCC [125], the age of the cohort reported would put the vast majority well beyond the menopause. Alternatively perhaps the gender distribution is pathophysiologically significant. In the age category 70–74 years for the UK in the median year of publication (1998), females constituted only 55% of the population [126] and yet 73% of thiazide-induced hyponatraemia patients in our meta-analysis were female.

It is not possible to draw meaningful conclusions regarding the prevalence of thiazide-induced hyponatraemia with respect to individual thiazide drugs from the available data, apart from observing that thiazide-induced hyponatraemia is reported with many thiazides including indapamide and chlortalidone, the two currently recommended thiazide-like diuretics for hypertension in the UK [4].

The detailed study of the phenotype and pathophysiology of patients with thiazide-induced hyponatraemia has the potential not only to improve clinical care of patients prescribed thiazides but also potentially to uncover novel pathophysiological insights into salt and water handling in the kidney which are clearly disturbed in these individuals. In the absence of a prospective trial exposing thousands of patients to thiazides with extensive follow-up (which is unlikely due to prohibitive expense and limited interest from pharmaceutical companies given the very old non-patented nature of thiazides), larger scale prospective observational studies with detailed phenotyping of thiazide-induced hyponatraemia patients is required. Such a study is already taking place across several acute hospitals throughout the UK (NIHR CRN portfolio identity 10795).

In conclusion this study found that patients with thiazide-induced hyponatraemia were characterized by advanced age, female gender, inappropriate natriuresis and mild hypokalaemia. Such patients had a normal BMI and were diagnosed later than the usual serum electrolyte monitoring interval of 7–14 days after thiazide commencement. Until further studies determine the optimal timing and frequency of electrolyte monitoring regimens it would seem prudent to be mindful of the development of hyponatraemia outside of the first fortnight of thiazide therapy.

Competing Interests

All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/coi_disclosure.pdf and declare Dr Glover reports a Clinician Scientist grant from Medical Research Council and a starter grant for clinical lecturers from the Academy of Medical Sciences, for the submitted work. Dr Glover and Dr Clayton report a grant from Otsuka, outside the submitted work in the previous 3 years. Professor Ferner reports providing expert medico-legal evidence on adverse drug reactions. There are no other relationships or activities that could appear to have influenced the submitted work. None of the funders had any role in study design, in the collection, analysis, and interpretation of data, in the writing of the report or in the decision to submit the article for publication.

This work was supported by a Clinician Scientist award from the Medical Research Council (MG) and an Academy of Medical Sciences starter grant for Clinical Lecturers (MG).

REFERENCES

- 1 Glover M, Mercier Zuber A, O'Shaughnessy KM. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT. *Cardiovasc Ther* 2011; 29: 68–76.
- 2 Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril): its use alone and combined with other antihypertensive agents. *JAMA* 1958; 166: 137–40.
- 3 Brown MJ. The choice of diuretic in hypertension: saving the baby from the bathwater. *Heart* 2011; 97: 1547–51.
- 4 NICE. Hypertension: clinical management of primary hypertension in adults. Clinical guideline CG127 2011. Available at <http://guidancencice.org.uk/CG127> (last accessed 1 May 2014).
- 5 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 2009; 338: b1665.
- 6 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. *JAMA* 2002; 288: 2981–97.
- 7 Glover M, Clayton J. Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis. *Cardiovasc Ther* 2012; 30: e219–26.
- 8 Glover M, O'Shaughnessy KM. Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and Thiazide-Induced Hyponatraemia. *Clin Exp Pharmacol Physiol* 2013; 40: 876–84.

- 9** Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. *Q J Med* 2006; 99: 505–11.
- 10** Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP. Thiazide diuretic prescription and electrolyte abnormalities in primary care. *Br J Clin Pharmacol* 2006; 61: 87–95.
- 11** Reynolds RM, Seckl JR. Hyponatraemia for the clinical endocrinologist. *Clin Endocrinol (Oxf)* 2005; 63: 366–74.
- 12** Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E, Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. *Nephrol Dial Transplant* 2014; 29: (Suppl. 2): i1–i39. doi:10.1093/ndt/gfu040.
- 13** Albrecht J, Werth VP, Bigby M. The role of case reports in evidence-based practice, with suggestions for improving their reporting. *J Am Acad Dermatol* 2009; 60: 412–8.
- 14** DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; 7: 177–88.
- 15** Stroup DF, Berlin JA, Morton SC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. *JAMA* 2000; 283: 2008–12.
- 16** Achinger SG, Moritz ML, Ayus JC. Dysnatremias: why are patients still dying? *South Med J* 2006; 99: 353–62.
- 17** Adrogué HJ, Madias NE. Hyponatraemia. *N Engl J Med* 2000; 342: 1581–9.
- 18** Al-Salman J, Pursell R. Hyponatremic encephalopathy induced by thiazide. *West J Med* 2001; 175: 87.
- 19** Ayus JC, Levine R, Arief A. Fatal dysnatraemia caused by elective colonoscopy. *BMJ* 2003; 326: 382–4.
- 20** Benfield GFA, Haffner C, Harris P, Stableforth DE. Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug. *Lancet* 1986; 328: 341.
- 21** Berl T, Rastegar A. A patient with severe hyponatraemia and hypokalaemia: osmotic demyelination following potassium repletion. *Am J Kidney Dis* 2010; 55: 742–8.
- 22** Cakir M. Significant hyperkalemia and hyponatraemia secondary to telmisartan/hydrochlorothiazide treatment. *Blood Press* 2010; 19: 380–2.
- 23** Coler C, Hoffman MD, Towle G, Hew-Butler T. Hyponatraemia in an 85-year-old hiker: when depletion plus dilution produces delirium. *Wilderness Environ Med* 2012; 23: 153–7.
- 24** Collier JG, Webb DJ. Severe thiazide-induced hyponatraemia during treatment with enalapril. *Postgrad Med J* 1987; 63: 1105–6.
- 25** Cundy T, Trafford JA. Efficacy of peritoneal dialysis in severe thiazide-induced hyponatraemia. *Postgrad Med J* 1981; 57: 734–5.
- 26** Eastell R, Edmonds CJ. Hyponatraemia associated with trimethoprim and a diuretic. *BMJ* 1984; 289: 1658–9.
- 27** Fadel S, Karmali R, Cogan E. Safety of furosemide administration in an elderly woman recovered from thiazide-induced hyponatraemia. *Eur J Intern Med* 2009; 20: 30–4.
- 28** Fuisz RE, Lauler DP, Cohen P. Diuretic-induced hyponatraemia and sustained antidiuresis. *Am J Med* 1962; 33: 783–91.
- 29** Gardner LB, Preston RA. University of Miami Division of Clinical Pharmacology Therapeutic Rounds: the water-intolerant patient and perioperative hyponatraemia. *Am J Ther* 2000; 7: 23–30.
- 30** Ghose RR. Reset osmostat after diuretic treatment. *BMJ* 1977; 2: 1063.
- 31** Gossain VV, Hagen GA, Sugawara M. Drug-induced hyponatraemia in psychogenic polydipsia. *Postgrad Med J* 1976; 52: 720–2.
- 32** Hamburger S, Koprivica B, Ellerbeck E, Covinsky JO. Thiazide-induced syndrome of inappropriate secretion of antidiuretic hormone: time course of resolution. *JAMA* 1981; 246: 1235–6.
- 33** Handler J. Well tolerated spironolactone-related hyponatraemia. *J Clin Hypertens (Greenwich)* 2008; 10: 317–21.
- 34** Husby S, Marthedal NJ. Hyponatraemia due to a thiazide diuretic. A case report. *Acta Med Scand* 1981; 210: 523–4.
- 35** Hussain I, Jan A, Doherty J, Hickey P. Severe symptomatic hyponatraemia. *Ir Med J* 2011; 104: 285–6.
- 36** Jen H-L, Tsai S-H, Wang C-J, Yin W-H, Young MS. Acute hyponatraemia and hypokalaemia associated with indapamide – a case report. *Acta Cardiol Sin* 2002; 18: 206–10.
- 37** Johnson E, Wright F. Thiazide-Induced hyponatraemia. *South Med J* 1983; 76: 1363–7.
- 38** Karp BI, Lauren R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatraemia. *Medicine (Baltimore)* 1993; 72: 359–73.
- 39** Kennedy RM, Earley LE. Profound hyponatraemia resulting from a thiazide-induced decrease in urinary diluting capacity in a patient with primary polydipsia. *N Engl J Med* 1970; 282: 1185–6.
- 40** Kone B, Gimenez L, Watson AJ. Thiazide-induced hyponatraemia. *South Med J* 1986; 79: 1456–7.
- 41** Lin SH, Chau T, Wu CC, Yang SS. Osmotic demyelination syndrome after correction of chronic hyponatraemia with normal saline. *Am J Med Sci* 2002; 323: 259–62.
- 42** Luft FC. Salt and water metabolism in clinical daily routine. *Internist* 1998; 39: 804–9.
- 43** Lundbom N, Laurila O, Laurila S. Central pontine myelinolysis after correction of chronic hyponatraemia. *Lancet* 1993; 342: 247–8.
- 44** Mataverde AQ, Abbasi AA, Hossain Z, Bissell GW. Hydrochlorothiazide-induced water intoxication in myxedema. *JAMA* 1974; 230: 1014–5.

- 45** Menashe G, Borer A, Gilad J, Horowitz J. Rhabdomyolysis after correction of severe hyponatraemia. *Am J Emerg Med* 2000; 18: 229–30.
- 46** Meuleman JR. Walking the tightrope: the challenge of elder care. *J Am Geriatr Soc* 1996; 44: 1466–8.
- 47** Miyasaka M, Hamaki T, Kami M, Hamabe Y. A patient with heatstroke associated with consciousness disturbance secondary to hyponatraemia: a case report. *J Med Case Rep* 2013; 7: 62.
- 48** Mok N-S, Tong C-K, Yuen H-C. Concomitant-acquired long QT and Brugada syndromes associated with indapamide-induced hypokalemia and hyponatremia. *Pacing Clin Electrophysiol* 2008; 31: 772–5.
- 49** Mouallem M, Brif I, Mayan H, Farfel Z. Prolonged therapy by the combination of furosemide and thiazide in refractory heart failure and other fluid retaining conditions. *Int J Cardiol* 1995; 50: 89–94.
- 50** Mount DB, Krahn TA. Hyponatraemia: case vignettes. *Semin Nephrol* 2009; 29: 300–17.
- 51** Moussa NA, Osman AR, Yahya TM. Acute hyponatremic encephalopathy after a cerebrovascular accident. *Am J Med Sci* 1998; 316: 56–9.
- 52** Mozes B, Pines A, Werner D, Olchovsky D, Lieberman P, Frankl O. Thiazide-induced hyponatraemia: an unusual neurologic course. *South Med J* 1986; 79: 629–31.
- 53** Onozaki A, Suzuki H, Imamura N, Katoh T, Watanabe T. Congenital nephrogenic diabetes insipidus with marked hyponatraemia. *Clin Exp Nephrol* 2001; 5: 265–7.
- 54** Orija IB, Cohen SB. An elderly woman with drug-induced coma in winter. *Cleve Clin J Med* 2001; 68: 25–32.
- 55** Ponte CD. A suspected case of thiazide-induced hyponatraemia. *Drug Intell Clin Pharm* 1982; 16: 699–700.
- 56** Ranta A, Wooten GF. Hyponatraemia due to an additive effect of carbamazepine and thiazide diuretics. *Epilepsia* 2004; 45: 879.
- 57** Roberts CJ, Channer KS, Bungay D. Hyponatraemia induced by a combination of hydrochlorothiazide and triamterene. *BMJ* 1984; 288: 1962.
- 58** Shah PJ, Greenberg WM. Water intoxication precipitated by thiazide diuretics in polydipsic psychiatric patients. *Am J Psychiatry* 1991; 148: 1424–5.
- 59** Sterns RH, Hix JK, Silver S. Treating profound hyponatraemia: a strategy for controlled correction. *Am J Kidney Dis* 2010; 56: 774–9.
- 60** Strykers PH, Stern RS, Morse BM. Hyponatraemia induced by a combination of amiloride and hydrochlorothiazide. *JAMA* 1984; 252: 389.
- 61** Van Assen S, Mudde AH. Severe hyponatraemia in an amiloride/hydrochlorothiazide-treated patient. *Neth J Med* 1999; 54: 108–13.
- 62** Wierzbicki AS, Ball SG, Singh NK. Profound hyponatraemia following an idiosyncratic reaction to diuretics. *Int J Clin Pract* 1998; 52: 278–9.
- 63** Wijnen H, Mesker P, Rikkert MO. Hyponatraemia caused by thiazide diuretics: be aware of drug combinations which enhance this effect. *Ned Tijdschr Geneesk* 2002; 146: 2109–10.
- 64** Yap HY, Lau CP. Hyponatraemic encephalopathy complicating thiazide reserpine preparation. *Postgrad Med J* 1992; 68: 149–50.
- 65** Aaseth JA, Tangen MK, Beitnes JO. Hyponatremic emergency – a serious side effect of thiazide treatment in the elderly. *Tidsskr Nor Laegeforen* 2001; 121: 921–3.
- 66** Adams KR, Martin JA. Electrolyte disorders in the elderly. *Drugs Aging* 1991; 1: 254–65.
- 67** Al Qahtani M, Alshahrani A, Alskaini A, Abukhalid N, Al Johani N, Al Ammari M, Al Swaidan L, Binsalih S, Al Sayyari A, Theaby A. Prevalence of hyponatraemia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. *Saudi J Kidney Dis Transpl* 2013; 24: 281–5.
- 68** Ambrosi P, Villani P, Bouvenot G. Hyponatraemia in elderly patients treated with thiazide diuretics and incited to drink abundantly during the heat wave. *Presse Med* 2004; 33: 535–6.
- 69** Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatraemia associated with death or neurologic damage in outpatients. *Am J Med* 1981; 70: 1163–8.
- 70** Bain PG, Egner W, Walker PR. Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage. *Lancet* 1986; 328: 634.
- 71** Bayer AJ, Farag R, Browne S, Pathy MS. Plasma electrolytes in elderly patients taking fixed combination diuretics. *Postgrad Med J* 1986; 62: 159–62.
- 72** Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. *Intern Med J* 2007; 37: 149–55.
- 73** Booker JA. Severe symptomatic hyponatraemia in elderly outpatients: the role of thiazide therapy and stress. *J Am Geriatr Soc* 1984; 32: 108–13.
- 74** Canning G, McKillop G, Slater SD. Dilutional hyponatraemia due to hydrochlorothiazide plus amiloride (Moduretic): not to be mistaken for the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). *Br J Clin Pract* 1988; 42: 41–2.
- 75** Chapman MD, Hanrahan R, McEwen J, Marley JE. Hyponatraemia and hypokalaemia due to indapamide. *Med J Aust* 2002; 176: 219–21.
- 76** Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatraemia. *J Natl Med Assoc* 2004; 96: 1305–8.
- 77** Coenraad MJ, Meinders AE, Vandenbroucke JP, Frölich M, Taal JCW, Bolk JH. Causes of hyponatraemia in the departments of internal medicine and neurosurgery. *Eur J Intern Med* 2003; 14: 302–9.
- 78** Cogan E, Abramow M. Diuretic-induced hyponatraemia in elderly hypertensive women. *Lancet* 1983; 322: 1249.

- 79** Donaldson M. Combination diuretics in the elderly. *Med J Aust* 1983; 1: 106.
- 80** Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatraemia. *J Clin Endocrinol Metab* 2009; 94: 123–9.
- 81** Fichman MP, Vorherr H, Kleeman C, Telfer N. Diuretic-induced hyponatraemia. *Ann Intern Med* 1971; 75: 853–63.
- 82** Furlanos S, Greenberg P. Managing drug-induced hyponatraemia in adults. *Aust Prescr* 2003; 23: 114–7.
- 83** Frenkel W, Deen P, Levi M, van den Born BJ. Determinants of thiazide-induced hyponatraemia in the elderly. *J Hypertens* 2010; 28: e545.
- 84** Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatraemia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. *Ann Intern Med* 1989; 110: 24–30.
- 85** Ghose RR. Letter: hyponatraemia and diuretics. *Lancet* 1975; 1: 587–9.
- 86** Hajjar I, Graves JW. Hyponatraemia in older women. *J Clin Hypertens* 2004; 6: 37–9.
- 87** Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. *Nephrol Dial Transplant* 2006; 21: 70–6.
- 88** Hung TY, Ho DD, So HM, Lo MW, Yeung VTF. Life-threatening diuretic-induced hyponatraemia: a review of seven patients. *Hong Kong Pract* 2002; 24: 337–43.
- 89** Hwang KS, Kim GH. Thiazide-induced hyponatraemia. *Electrolyte Blood Press*, 2010; 8: 51–7.
- 90** Johnson C, Webb L, Daley J, Spathis GS. Hyponatraemia and Moduretic-grand mal-seizures: a review. *J R Soc Med* 1989; 82: 479–83.
- 91** Jolobe OMP. Diuretic-induced hyponatraemia in elderly hypertensive women. *J Hum Hypertens* 2003; 17: 151.
- 92** Kalksma R, Leemhuis MP. Hyponatraemia caused by thiazide diuretics: be aware of drug combinations which enhance this effect. *Ned Tijdschr Geneeskd* 2002; 146: 1521–5.
- 93** Kinoshita H, Kobayashi K, Yaguramaki T, Yasuda M, Fujiki K, Tomiyama J, Koga N, Yakushiji F. Losartan potassium/hydrochlorothiazide and hyponatraemia: case series of 40 patients. *Hum Exp Toxicol* 2011; 30: 1409–14.
- 94** Mackay M. Hyponatraemia and diuretics. *N Z Med J* 1983; 96: 635.
- 95** Malin JW, Kolstad K, Hozack WJ, Rothman RH. Thiazide-induced hyponatraemia in the postoperative total joint replacement patient. *Orthopedics* 1997; 20: 681–3.
- 96** Mathew TH, Boyd IW, Rohan AP. Hyponatraemia due to the combination of hydrochlorothiazide and amiloride (Moduretic): Australian spontaneous reports 1977–1988. *Med J Aust* 1990; 152: 308–9.
- 97** McDowell SE, Coleman JJ, Evans SJW, Gill PS, Ferner RE. Laboratory monitoring and adverse patient outcomes with antihypertensive therapy in primary care. *Pharmacoepidemiol Drug Saf* 2010; 19: 482–9.
- 98** Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z. Cardiac conduction defects associated with hyponatraemia. *Clin Cardiol* 1991; 14: 165–8.
- 99** Musch W, Decaux G. Utility and limitations of biochemical parameters in the evaluation of hyponatraemia in the elderly. *Int Urol Nephrol* 2001; 32: 475–93.
- 100** Oles KS, Denham JW. Hyponatraemia induced by thiazide-like diuretics in the elderly. *South Med J* 1984; 77: 1314–5.
- 101** Pinnock CA. Hyponatraemia associated with hydrochlorothiazide treatment. *BMJ* 1978; 1: 48.
- 102** Rask E, Olsson T, Hagg E, Anderson P, Svensson I. Hyponatraemia caused by diuretics in elderly women. Risk of adverse effects. Be careful with indications. *Lakartidningen* 1996; 83: 4269–70.
- 103** Rastogi D, Pelter MA, Deamer RL. Evaluations of hospitalizations associated with thiazide-associated hyponatraemia. *J Clin Hypertens* 2012; 14: 158–64.
- 104** Rodenburg EM, Hoorn EJ, Ruiters R, Lous JJ, Hofman A, Uitterlinden AG, Stricker BH, Visser LE. Thiazide-associated hyponatraemia: a population-based study. *Am J Kidney Dis* 2013; 62: 67–72.
- 105** Rosner MH. Severe hyponatraemia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. *Am J Med Sci* 2004; 327: 109–11.
- 106** Shapiro DS, Sonnenblick M, Galperin I, Melkonyan L, Munter G. Severe hyponatraemia in elderly hospitalized patients: prevalence, aetiology and outcome. *Intern Med J* 2010; 40: 574–80.
- 107** Sharabi Y, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH, Grossman E. Diuretic induced hyponatraemia in elderly hypertensive women. *J Hum Hypertens* 2002; 16: 631–5.
- 108** Sonnenblick M, Rosin AJ. Significance of the measurement of uric acid fractional clearance in diuretic induced hyponatraemia. *Postgrad Med J* 1986; 62: 449–52.
- 109** Sonnenblick M, Algur N, Rosin A. Thiazide-induced hyponatraemia and vasopressin release. *Ann Intern Med* 1989; 110: 751.
- 110** Takeshita M, Miyao M, Mizuno Y. Thiazide diuretics for hypertensive treatment induced severe hyponatraemia with consciousness disturbance in two elderly cases. *Nippon Ronen Igakkai Zasshi* 2010; 47: 257–61.
- 111** Tarssanen L, Huikko M, Rossi M. Amiloride-induced hyponatraemia. *Acta Med Scand* 1980; 208: 491–4.
- 112** Thuesen L, Frost JW. Hyponatraemia during thiazide therapy. *Ugeskr Laeger* 1980; 142: 1933–4.

- 113** van Brummelen P, Schalekamp M, de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. *Acta Med Scand* 1978; 204: 151–7.
- 114** Van Wijngaarden T, Dekker J. Two confused patients. *Huisarts Wet* 2010; 53: 337–9.
- 115** Yong TY, Huang JE, Lau SY, Li JY. Severe hyponatremia and other electrolyte disturbances associated with indapamide. *Curr Drug Saf* 2011; 6: 134–7.
- 116** Zalin AM, Hutchinson CE, Jong M, Matthews K. Hyponatraemia during treatment with chlorpropamide and Moduretic (amiloride plus hydrochlorothiazide). *BMJ* 1984; 289: 659.
- 117** Chow KM, Szeto CC, Wong TYH, Leung CB, Li PKT. Risk factors for thiazide-induced hyponatraemia. *QJM* 2003; 96: 911–7.
- 118** Chow KM, Szeto CC, Kwan BCH, Ma TKW, Leung CB, Li PKT. Fracture risk after thiazide-associated hyponatraemia. *Intern Med J* 2012; 42: 760–4.
- 119** Chow KM, Szeto CC, Kwan BCH, Li PKT. Influence of climate on the incidence of thiazide-induced hyponatraemia. *Int J Clin Pract* 2007; 61: 449–52.
- 120** McDowell SE, Thomas SK, Coleman JJ, Aronson JK, Ferner RE. A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. *J R Soc Med* 2013; 106: 87–95.
- 121** McDowell SE, Ferner RE. Biochemical monitoring of patients treated with antihypertensive therapy for adverse drug reactions. *Drug Saf* 2011; 34: 1049–59.
- 122** Burton TJ, Salsbury J, Hood S, Brown MJ. Conn's syndrome unmasked by thiazide-induced hypokalaemia. *Br J Hosp Med* 2011; 72: 530–1.
- 123** Lalioti M, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP. Wnk 4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. *Nat Genet* 2006; 38: 1124–32.
- 124** Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. *Am J Med* 1967; 42: 790–806.
- 125** Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC. Estradiol enhances thiazide-sensitive NaCl cotransporter density in the apical plasma membrane of the distal convoluted tubule in ovariectomized rats. *J Clin Invest* 1998; 101: 1661–9.
- 126** ONS. Population Estimates for UK, England and Wales, Scotland and Northern Ireland – mid 1991 to mid 2000. Available at <http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/mid-1991-to-mid-2000-local-authority-population-studies/index.html> (last accessed 1 September 2013).

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Figure S1

Proportion of patients with thiazide-induced hyponatraemia who were female

Figure S2

Summary of mean age in patients with thiazide-induced hyponatraemia

Figure S3

Summary of mean body mass index in patients with thiazide-induced hyponatraemia (kg m⁻²)

Figure S4

Summary of mean duration from thiazide initiation to presentation with thiazide-induced hyponatraemia (days)

Figure S5

Proportion of patients with thiazide-induced hyponatraemia who reported fatigue

Figure S6

Proportion of patients with thiazide-induced hyponatraemia who reported dizziness

Figure S7

Proportion of patients with thiazide-induced hyponatraemia who reported confusion

Figure S8

Proportion of patients with thiazide-induced hyponatraemia who reported vomiting

Figure S9

Proportion of patients with thiazide-induced hyponatraemia who reported falls

Figure S10

Proportion of patients with thiazide-induced hyponatraemia who reported nausea

Figure S11

Proportion of patients with thiazide-induced hyponatraemia who were reported to be unconscious

Figure S12

Proportion of patients with thiazide-induced hyponatraemia who reported weakness

Figure S13

Proportion of patients with thiazide-induced hyponatraemia who reported neurological symptoms

Figure S14

Proportion of patients with thiazide-induced hyponatraemia who had seizures

Figure S15

Proportion of patients with thiazide-induced hyponatraemia who had cardiovascular disease

Figure S16

Proportion of patients with thiazide-induced hyponatraemia who had diabetes mellitus

Figure S17

Proportion of patients with thiazide-induced hyponatraemia who took hydrochlorothiazide

Figure S18

Proportion of patients with thiazide-induced hyponatraemia who took indapamide

Figure S19

Proportion of patients with thiazide-induced hyponatraemia who took Moduretic® (hydrochlorothiazide with amiloride)

Figure S20

Proportion of patients with thiazide-induced hyponatraemia who took bendroflumethiazide (bendrofluazide)

Figure S21

Proportion of patients with thiazide-induced hyponatraemia who took Dyazide® (hydrochlorothiazide with triamterene)

Figure S22

Proportion of patients with thiazide-induced hyponatraemia who took chlortalidone

Figure S23

Proportion of patients with thiazide-induced hyponatraemia who were also taking an angiotensin converting enzyme (ACE) inhibitor

Figure S24

Proportion of patients with thiazide-induced hyponatraemia who were also taking non-steroidal anti-inflammatory drugs

Figure S25

Proportion of patients with thiazide-induced hyponatraemia who were also prescribed a non-thiazide diuretic

Figure S26

Proportion of patients with thiazide-induced hyponatraemia who were also taking antidepressants

Figure S27

Proportion of patients with thiazide-induced hyponatraemia who were also taking potassium supplements

Figure S28

Proportion of patients with thiazide-induced hyponatraemia who were also taking angiotensin II receptor blockers

Figure S29

Summary of mean concentration of serum sodium in patients with thiazide-induced hyponatraemia (mM)

Figure S30

Summary of mean concentration of serum potassium in patients with thiazide-induced hyponatraemia (mM)

Figure S31

Summary of mean concentration of serum creatinine in patients with thiazide-induced hyponatraemia ($\mu\text{mol l}^{-1}$)

Figure S32

Summary of mean serum osmolality in patients with thiazide-induced hyponatraemia (mosm kg^{-1})

Figure S33

Summary of mean urinary osmolality in patients with thiazide-induced hyponatraemia (mosm kg^{-1})

Figure S34

Summary of mean concentration of urinary sodium in patients with thiazide-induced hyponatraemia (mM)

Table S1

Study characteristics and quality scores of single thiazide-induced hyponatraemia case reports

Table S2

Characteristics and quality scores of studies included in the meta-analysis i.e. where more than one thiazide-induced hyponatraemia patient was reported per study

Table S3

Meta-analyses of demographic characteristics of patients with thiazide-induced hyponatraemia by analysis of quality score, year of publication and age of patient

Table S4

Meta-analyses of clinical characteristics of patients with thiazide-induced hyponatraemia by analysis of quality score, year of publication and age of patient. Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions

Table S5

Meta-analyses of drug history of patients with thiazide-induced hyponatraemia by analysis of quality score, year of publication and age of patient. Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions

Table S6

Meta-analyses of laboratory characteristics of patients with thiazide-induced hyponatraemia by analysis of quality score, year of publication and age of patient